London, UK: 20th June 2007; Innate Pharma S.A., a biopharmaceutical company developing new drug classes targeting innate immunity, today announced it has entered into a in-licensing agreement with Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, on novel Toll like receptor (TLR) agents.
